相关实验视频

Updated: Jun 22, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

通过准PI3K/Akt/p53信号通路进行新型黄素衍生物的体外抗癌研究

Huixian Zhou¹, Zhiwen Wu¹, Yannan Zhang¹

¹School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510006, People's Republic of China.

Molecular diversity

|July 1, 2024

概括

一种新型的黄素衍生物,化合物6a,有效地抑制MCF-7乳腺癌细胞的增殖,对正常细胞的毒性较低. 它通过向PI3K/Akt/p53通路来诱导亡,显示出作为向癌症治疗的希望.

科学领域:

药用化学医学化学
癌症生物学癌症生物学
分子药理学分子药理学

背景情况:

黄素的衍生品正在探索抗癌性质.
针对癌细胞增殖和亡是有效治疗的关键.
PI3K/Akt/p53通路是细胞存活和增殖的关键调节者.

研究的目的:

合成新型黄素衍生物与无NO捐赠部分.
评估这些衍生物对各种癌症和正常细胞系的细胞毒性.
研究最强效的衍生物化合物6a在MCF-7细胞中的作用机制.

主要方法:

通过以太化,核替代和诺维纳格尔凝结进行合成.
对A549,Hela,HepG2,MCF-7,HT-29,LO-2和HK-2细胞系进行细胞毒性测定.
在体外机理学研究,包括细胞循环分析,ROS检测,西部斑点和分子对接.

主要成果:

化合物6a显著抑制了MCF-7细胞增殖,对正常细胞的毒性较低.
化合物6a诱导G2/M细胞周期停止和MCF-7细胞的细胞亡,以剂量依赖的方式.
西部布洛特分析显示PI3K减少和p53增加,切割的caspase-9和切割的caspase-3表达;分子对接证实PI3K结合.

结论:

化合物6a是一种有前途的抗癌剂,向MCF-7细胞.
它作为潜在的PI3K抑制剂起作用,破坏PI3K/Akt/p53通路.
需要进一步研究6a化合物作为乳腺癌的治疗剂.

关键词:

这是一种抗瘤药物.黄素的衍生品黄素的衍生品我们知道Nagel凝结.通过PI3K/Akt/p53路径.

更多相关视频

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...